2 reports

  • MAY 04, 2017: SPERO THERAPEUTICS RECEIVES GRANT FROM NATIONAL INSTITUTES OF HEALTH TO EXPLORE NOVEL TREATMENT COMBINATIONS FOR TUBERCULOSIS
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2016

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1 2018 Summary DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H1...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017
  • VXC-486 - DRUG PROFILE

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2017 Summary DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2017, outlays comprehensive...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC